The dermatologic aspects of COVID-19 infection are reviewed and identify the skin complications seen and preventative measures that can be taken.
Tirbanibulin is superior to vehicle at 2 months for the treatment of actinic keratosis, but almost half of patients who had a complete response experienced recurrence of lesions at one year.
The approval was based on data from 2 multicenter, randomized, double-blind, phase 3 trials (ClinicalTrials.gov: NCT03285477 [N=351] and NCT03285490 [N=351]) that compared the efficacy and safety of Klisyri ointment to placebo in adults with AK on the face or scalp.
The prevalence and characteristics of hidradenitits suppurative-related pain in patients was assessed in a large study.
The prevalence and patterns of cutaneous manifestations in COVID-19 in patients with skin of color is reported.
A summary of tips for capturing high quality images of patients with skin of color is provided.
Baseline BMI and change in BMI of patients with HS and control patients before and after diagnosis of HS were compared.
The cutaneous signs thus reported as COVID-19 related, their incidence, clinic-pathologic features, and diagnostic and prognostic values are described.
Study authors sought to determine whether surgical antimicrobial prophylaxis administration following cord clamping led to an increase risk of surgical site infections.
An update on the advances in CBD research and dermatology is provided.